Het effect van galantamine op de ecg- geleidingstijden

I. C. Jobse1,2, R. A. M. de Jonckheere3
1arts in op leiding tot klinisch geriater, afdeling klinische geriatrie, Amphia Ziekenhuis, Breda, The Netherlands
2Struitenweg 24 c, Rotterdam, The Netherlands
3klinisch geriater, afdeling klinische geriatrie, Amphia Ziekenhuis, Breda, The Netherlands

Tóm tắt

Từ khóa


Tài liệu tham khảo

Cummings JL. Use of cholinesterase inhibitors in clinical practice. Evidence – based recommendations. Am J Geriatr Psychiatry 2003; 11; 131–145

Masuda Y, Kawamura. Acetylcholinesterase inhibitor (Donepezil Hydrochloride) reduces heart rate variability. Journal of cardiovascular pharmacology. 41 (suppl.1): S67-S71

Leitch A, McGinness P, Wallbridge D. Calculate the QT interval in patients taking drugs for dementia BMJ. 2007;335(7619):557.

Suleyman T, Tevfik P, Abdulkadir G et al. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J. 2006;23 (8):641–2

Leentjens AF, Kragten JA. Complete atrioventricular block during galantamine therapy. Ned Tijdschr Geneeskd. 2006;150 (10):563–6

Bordier P, Garrigue S, Lanusse S et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s disease. CNS Drugs 2006;20 (5): 411–417

Doody RS, Corey–Bloom J, Zhang R. Safety and tolerability of donepezil at doses up to 20 mg/ day. Results from a pilot study in patients with Alzheimer’s disease. Drugs Aging 2008: 25 (2): 163–174.

Boada-Rovira M, Brodaty H, Cras P et al. Efficacy and safety of donepezil in Alzheimer’s disease. Drugs Aging 2004;21 (1):43–53.

Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. The Annals of Pharmacotherapy. 2008;42 (2):278–83

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane database syst. Rev. 2006;(1): CD005593

Gill S.S, Anderson GM, Fischer HD et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. A population-based cohort study. Arch Intern Med. 2009;169 (9):867–73

Hernandez RK, Farwell W, Cantor MD et al. Cholinesterase Inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. J Am Geriatr Soc 2009 57 (11); 1997–2003.

Morganroth J, Graham S, Hartman R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol. 2002;42(5):558–68

Isik AT, Bozoglu E, Naharci MI et al. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer’s disease. Am J Geriatr Pharmacother. 2010; 8 (5):454–9.

Isik AT, Yildiz GB, Bozoglu E. Cardiac safety of donepezil in elderly patients with Alzheimer disease. Intern Med. 2012; 51(6):575–8.

Isik AT, Bozoglu E. Yay A. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012; 27(3):171–4.

Cheng S, Keyes MY, Larson MG et al. Long term outcomes in individuals with prolonged PR interval or first degree atrioventriculair block JAMA 2009; 301 (24): 2571–7.